tbuckley/cabot-search huggingface dataset:
MICROBIC LATENCY AFTER INFECTIONS.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human Antibodies versus hydroxyethyl radical recognizes specific epitopes on the plasma membrane of isolated hepatocytes exposed to ethanol . Dept. of Medical Sciences, University of Torino, @Div. of Gastroenterology, Mauriziano Hospital, Torino, Italy, *Dept. of Medical Biochemistry &amp; Biophysics, Karolinska Institut, Stockholm, Sweden
Journal: Hepatology (1995)
Rapid electrical stimulation of contraction modulates gap junction protein in neonatal rat cultured cardiomyocytesInvolvement of mitogen-activated protein kinases and effects of angiotensin ii-receptor antagonist
Authors: N INOUE, T OHKUSA, T NAO, J LEE, T MATSUMOTO, Y HISAMATSU, T SATOH, M YANO, K YASUI, I KODAMA
Journal: Journal of the American College of Cardiology (2004)
Altered Asia loglycoproteind receptor density in livers of portacaval-shunted rats detected by quantitative functional imaging Transplant Division, Dept. of Surgery and Nuclear Medicine Division, Dept. of Radiology*, University of California, Davis
Journal: Hepatology (1995)

We have synthesized poly-γ-glutamic acid (PGA) modified with a synthetic trivalent glyco-ligand (TriGalNAc) for the hepatocyte asialoglycoprotein receptor (ASGP-R). We investigated in vivo distribution of unmodified PGA and TriGalNAc-modified PGA (TriGalNAc-PGA) in mice after intravenous injection. Most of unmodified PGA administered was transported to the bladder over 20–80 min, suggesting a rapid excretion of unmodified PGA into urine. In contrast, TriGalNAc-PGA was found exclusively in the liver over the same period of time. We further synthesized TriGalNAc-PGA–primaquine conjugate (TriGalNAc-PGA–PQ), and investigated binding, uptake, and catabolism of the conjugate by rat hepatocytes. Our studies indicated that approximately 250 ng per million cells of the conjugate bound to one million rat hepatocytes at 0 °C, and approximately 2 μg per million cells of the conjugate was taken up over 7 h incubation at 37 °C. Furthermore, our results suggested that TriGalNAc-PGA–PQ was almost completely degraded over 24 h, and small degradation products were secreted into cell culture medium.The results described in this report suggest that the TriGalNAc ligand can serve as an excellent targeting device for delivery of PGA-conjugates to the liver hepatocytes, and rat hepatocytes possess sufficient capacity to digest PGA even modified with other substituents.
The Lymphomas: Current Concepts in Pathogenesis and Management
Journal: JNCI Journal of the National Cancer Institute (1990)

The Lymphomas: Current Concepts in Pathogenesis and Management Get access JNCI: Journal of the National Cancer Institute, Volume 82, Issue 13, 4 July 1990, Page 1165, https://doi.org/10.1093/jnci/82.13.1165 Published: 04 July 1990
Health and the ozone layer.
Authors: J. M. Elwood
Journal: BMJ (1988)

surgery for locally recurrent disease, a figure which we would regard as higher than desirable.Though the results of our studies and those of others may lead us to revise our approach in due course, we think that meantime we should continue to explain to our elderly patients that there are two forms of treatment available.One entails immediate surgery, the other a trial of tamoxifen, surgery then being required only if the disease is not controlled, which is likely in less than half of those treated.The choice is theirs.
Reduced re-excisions while conserving tissue volume resected in DCIS patients.
Authors: Beth Cutler Freedman, Susan K. Boolbol, Costanza Cocilovo, Lorraine Tafra
Journal: Journal of Clinical Oncology (2012)

144 Background: The ability to obtain negative margins with a single surgical procedure remains a challenge, particularly in patients with ductal carcinoma in situ (DCIS). Many techniques have been reported to lower the positive margin rate, at a cost of additional tissue resected. A novel device (MarginProbe, Dune Medical Devices, Inc.) is intended to provide surgeons with real time, intraoperative detection of cancerous tissues at the margins of excised specimens. An analysis was performed to determine the impact on tissue volume of the previously reported improvement in candidates for re-excision associated with device use for patients with a DCIS component. Methods: 596 patients undergoing breast conservation using wire localization were randomized in a prospective, international, multicenter (n=21) study. Randomization occurred in the operating room, following standard of care lumpectomy, including palpation and any indicated additional resections. Positive readings required additional resections of the cavity; device was used on main lumpectomy specimen only. Pathologists were blinded to study arm. Tissue volume of all specimens and resections was recorded. Since reducing candidates for re-excision requires removing additional tissue associated with cancer, we looked at total tissue volume removed across all surgeries, to assess the final impact to the patient. Results: Total tissue volumes removed during all surgeries (lumpectomy and re-excisions) for patients with DCIS alone was similar between the study group and control group, while the decrease in candidates for re-excision was significant (13% vs. 37%, p=0.004). For patients with DCIS and invasive carcinoma, the total volume excised was also similar, and the decrease in re-excision candidates was significant (13% vs. 33%, p&lt;0.001). Conclusions: Unlike other techniques for reducing re-excisions, device use does not require an increase in tissue volume to achieve a significant reduction in the number of candidates for re-excision. [Table: see text]
Orthotopic liver transplantation for alcoholic cirrhosis
Authors: T. E. Starzl
Journal: JAMA (1988)

Fifteen patients with Laennec's cirrhosis underwent orthotopic liver transplantation between 1963 and the end of 1979.The first eight patients died perioperatively or within two months, but four of the next seven patients had long survival; three are still alive after 11 to 14 years.After the introduction of cyclosporine therapy, 41 more patients with alcoholic cirrhosis were treated with liver transplantation from 1980 to June 1987.The one-year survival is 73.2%, and, after one to three years, 28 (68%) of the recipients are living.Of the 35 patients in the combined old and new series who lived for six months or longer, only two returned to alcohol abuse.Social and vocational rehabilitation has been the rule in these recipients who were selected primarily because of urgency of need, because they or their families insisted on treatment, and because they and their families thereby committed themselves to long-standing programs of alcoholism care.The use of orthotopic liver transplantation to treat patients with Laennec's cirrhosis has been criticized by health care personnel or even prohibited by agencies responsible for health care funding. 1 To help judge the merit of such negative attitudes, we have examined the fate of 56 alcoholic recipients of liver transplants treated between 1963 and July 1987, with an emphasis on patients treated after the introduction of cyclosporine-steroid therapy in 1979.
TESTIMONIALS.
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transactions of the World's Columbian Dental Congress, in two volumes.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infantile colitis.
Authors: S M Hill, P J Milla
Journal: BMJ (1991)

cyclosporin rinse (swish and spit) proved helpful without causing systemic side effects and offered the prospect of longer remissions. 7Finally, in recalcitrant cases treatment with oral psoralens and ultraviolet A (PUVA) may be considered, though it may confer that most absurd of all status symbols, a genuine tan inside the mouth."Erasmus Wilson would have been glad to hear of these developments, but sorry that the cause of his disease is still not known.
DNMT3A Mutations in Acute Myeloid Leukemia-Stability During Disease Evolution and the Clinical Implication
Authors: Hsin-An Hou, Yuan-Yeh Kuo, Chieh-Yu Liu, Wen-Chien Chou, Ming Cheng Lee, Chien-Yuan Chen, Liang-In Lin, Mei-Hsuan Tseng, Chi-Fei Huang, Ying-Chieh Chiang, Fen-Yu Lee, Ming-Chih Liu, Chia-Wen Liu, Jih-Luh Tang, Ming Yao, Shang-Yi Huang, Bor-Sheng Ko, Szu-Chun Hsu, Shang-Ju Wu, Woei Tsay, Yao-Chang Chen, Hwei-Fang Tien
Journal: Blood (2011)
Home Visit
Authors: Thomas E. Edes
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ventricular Septal Defect with Aortic Valve Incompetence: Surgical Considerations
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Re: Guido Barbagli, Massimo Lazzeri. Clinical Experience with Urethral Reconstruction Using Tissue-engineered Oral Mucosa: A Quiet Revolution. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.043
Authors: Nadir I Osman, Christopher R Chapple, Sheila MacNeil
Journal: European Urology (2015)
Liver contains heparin-binding growth factors as the major growth factor for cultured fibroblasts
Authors: T Nagasaki
Journal: Hepatology (1991)

The presence of heparin-binding growth factors in liver was investigated by measuring the DNA synthesis stimulatory activity of liver extracts using quiescent fibroblasts as target cells. It was found that cytosolic fractions of mouse, rat and human liver, as well as isolated rat hepatocytes, contain a large amount of growth stimulatory activity. Most liver cytosolic activity is due to heparin-binding growth factors, because > 90% of the activity bound to a heparin affinity column in the presence of 0.8 mol/L NaCl, and was quantitatively eluted with 2 mol/L NaCl. Purification of these factors from both mouse and rat liver indicated the presence of both heparin-binding growth factor-1 and 2 in liver extracts. The level of the heparin-binding growth factors, as estimated from the biological activity, is approximately 1 μg/gm mouse liver and 0.1 μg/gm rat and human liver. Heparin-binding growth factor-1–like factors were 10 times as abundant as heparin-binding growth factor-2–like factors. These data indicate that the cytosolic fractions of mouse, rat and human liver contain heparin-binding growth factors as the primary growth factor for fibroblasts, and heparin binding growth factor-1–like molecules account for most of the cytosolic activity in both mouse and rat liver. (HEPATOLOGY 1991;13:6–14).
First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.
Authors: S. K. Sandhu, R. M. Wenham, G. Wilding, M. McFadden, L. Sun, C. Toniatti, M. Stroh, C. L. Carpenter, J. S. De Bono, W. R. Schelman
Journal: Journal of Clinical Oncology (2010)

3001 Background: MK-4827 is a potent, selective, PARP 1/2 inhibitor with IC50 of 3.8nM. MK-4827 induces selective synthetic lethality in homologous recombination (HR) repair deficient tumors with BRCA1/2 loss and tumor cell lines with non-BRCA-related HR defects, supporting clinical utility in sporadic tumors. Methods: MK4827 was administered orally once daily in cohorts of 3-6 pts, enriched for BRCA-deficient and sporadic cancers associated with HR repair defects. Dose escalation was guided by toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) data. Results: 39 pts (male 10, female 29; median age 58 years; 11 BRCA mutation carriers) were treated at 7 successive dose levels [30mg (6), 40mg (3), 60mg (7), 80mg (6), 110mg (5), 150mg (6), 210mg (6)] on days 1-21 of a 28 day cycle (C) in C1, followed by continuous dosing. Overall, dose-limiting toxicity was observed in 3 pts: grade (G) 3 fatigue in 1/6 pts at 30mg, reversible G3 pneumonitis in 1/6 pts at 60mg, and G3 anorexia in 1/6 pts at 210mg. Other MK-4827 related G1-2 reversible adverse events include nausea and myelosuppression. Preliminary PK data is approximately dose proportional with a mean terminal t1/2 of 40 hours (range 27-57). PD studies confirmed consistent PARP inhibition in peripheral blood mononuclear cells at doses of > 110 mg. Antitumor activity was observed in both sporadic and BRCA-deficient cancers. 3 pts with serous ovarian cancer had prolonged RECIST partial responses (PR) for 17+, 22+, 44+ weeks (w) (1 sporadic platinum sensitive ovarian cancer and 2 BRCA-deficient ovarian cancers). Furthermore, a patient with BRCA-deficient breast cancer had an unconfirmed PR and disease stabilization was seen in 1 patient with sporadic serous ovarian cancer for > 44 w and 2 pts with BRCA-deficient serous ovarian cancer for > 16 w. 1 patient with heavily pretreated non-small cell lung cancer has ongoing stable disease for > 42 w. Conclusions: MK-4827 is well tolerated, blocks PARP and has promising antitumor activity in both BRCA-deficient and sporadic cancers. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck Merck Merck Merck Merck
FRI0271 Stratification of sle patients for improved diagnosis and treatment
Authors: H. Idborg, S. Rännar, G. Oliynyk, J. Forshed, R. M. Branca, M. Donten, K. Bennett, J. Gustafsson, A. Vikerfors, K. Elvin, L. Truedsson, B. Nilsson, I. Gunnarsson, J. Trygg, J. Lehtiö, T. Lundstedt, E. Svenungsson, P.-J. Jakobsson
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Systemic autoimmune diseases (SAIDs) affect about 2 % of the population in Western countries. Sufficient diagnostic criteria are lacking due to the heterogeneity within diagnostic categories and apparent overlap regarding symptoms and patterns of autoantibodies between different diagnoses. Systemic lupus erythematosus (SLE) is regarded as a prototype for SAIDs and we hypothesize that subgroups of patients with SLE may have different pathogenesis and should consequently be subject to different treatment strategies. <h3>Objectives</h3> Our goal is to find new biomarkers to be used for the identification of more homogenous patient populations for clinical trials and to identify sub-groups of patients with high risk of for example cardiovascular events. <h3>Methods</h3> In this study we have utilized 320 SLE patients from the Karolinska lupus cohort and 320 age and gender matched controls. The SLE cohort was characterized based on clinical, genetic and serological data and combined by multivariate data analysis in a systems biology approach to study possible subgroups. A pilot study was designed to verify and investigate suggested subgroups of SLE. Two main subgroups were defined: One group was defined as having SSA and SSB antibodies and a negative lupus anticoagulant test (LAC), i.e., a "Sjögren-like" group. The other group was defined as being negative for SSA and SSB antibodies but positive in the LAC test. i.e. an "APS-like" group. EDTA-plasma from selected patients in these two groups and controls were analysed using a mass spectrometry (MS) based proteomic and metabolomic approach. Pathway analysis was then performed on the obtained data. <h3>Results</h3> Our pilot study showed that differences in levels of proteins and metabolites could separate disease groups from population controls. The profile/pattern of involved factors in the complement system supported a division of SLE in two major subgroups, although each individual factor was not significantly different between subgroups. Complement factor 2 (C2) and membrane attack complex (MAC) were analyzed in the entire cohort with complementary methods and C2 verifies our results while the levels of MAC did not differ between SLE subgroups. The generated metabolomics data clearly separated SLE patients from controls in both gas chromatography (GC)-MS and liquid chromatography (LC)-MS data. We found for example that tryptophan was lower in the SLE patients compared to controls. <h3>Conclusions</h3> Our systems biology approach may lead to a better understanding of the disease and its pathogenesis, and assigning patients into subgroups will result in improved diagnosis and better outcome measures of SLE. <b>Disclosure of Interest</b>: None Declared
Pancreas Transplantation
Authors: A. Benedict Cosimi
Journal: JAMA (1989)

Insulin-dependent diabetes mellitus is a common disorder with at least 100 000 new cases identified worldwide each year. Fifteen to 20 years later, approximately half of these patients will have developed the devastating microangiopathic complications of the disease despite reasonable control of hyperglycemia by currently available medical regimens. Since extensive experimental evidence suggests this dismal prognosis can be averted only by uninterrupted scrupulous control of both hyperglycemic and hypoglycemic episodes, replacement of the patients' inadequate insulin delivery system by transplantation has been pursued as an attractive therapeutic approach for nearly 25 years. Until recently, the success rate following pancreas transplantation was so marginal that attempts to develop the procedure were properly limited to a handful of investigators particularly interested in the field. Now, however, more acceptable survival rates are achievable because of refinements in the surgical aspects of the procedure and advances in immunosuppressive management of allograft recipients. This has
The Safety of Transdermal Nicotine as an Aid to Smoking Cessation in Patients with Cardiac Disease and Lack of Efficacy of Transdermal Nicotine in Smoking Cessation
Journal: New England Journal of Medicine (2007)

Correction from The New England Journal of Medicine — The Safety of Transdermal Nicotine as an Aid to Smoking Cessation in Patients with Cardiac Disease and Lack of Efficacy of Transdermal Nicotine in Smoking Cessation
&lt;emph type="ital"&gt;A Cover Without Art&lt;/emph&gt;
Authors: M. Therese Southgate
Journal: JAMA (2008)

Editor's Note: It has become a tradition for JAMA to omit a cover image on the theme issue devoted to HIV/AIDS. Once again we observe this tradition. A Cover Without Art appeared previously on July 10, 1996; July 1, 1998; July 12, 2000; July 10, 2002; July 14, 2004; and August 16, 2006.